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systemic inflammation
Anne Mette L Vinther1*, Kerstin Skovgaard2, Peter MH Heegaard2 and Pia H Andersen3Abstract
Background: In horses, insights into the innate immune processes in acute systemic inflammation are limited even
though these processes may be highly important for future diagnostic and therapeutic advances in high-mortality
disease conditions as the systemic inflammatory response syndrome (SIRS) and sepsis. Therefore, the aim of this
study was to investigate the expression of 31 selected blood leukocyte immune genes in an equine model of acute
systemic inflammation to identify significantly regulated genes and to describe their expression dynamics during a
24-h experimental period. Systemic inflammation was induced in 6 adult horses by the intravenous injection of
1 μg lipopolysaccharide (LPS) per kg btw. Sixteen blood samples were collected for each horse at predetermined
intervals and analyzed by reverse transcription quantitative real-time PCR. Post-induction expression levels for each
gene were compared with baseline levels.
Results: Systemic inflammation was confirmed by the presence of clinical and hematological changes which
were consistent with SIRS. The clinical response to LPS was transient and brief as all horses except one showed
unaltered general demeanor after 24 h. Twenty-two leukocyte genes were significantly regulated at at least one
time point during the experimental period. By close inspection of the temporal responses the dynamic changes
in mRNA abundance revealed a very rapid onset of both pro- and anti-inflammatory mediators and a substantial
variation in both expression magnitudes and duration of changes between genes. A majority of the 22 significantly
regulated genes peaked within the first 8 h after induction, and an on-going, albeit tightly controlled, regulation was
seen after 24 h despite approximate clinical recovery.
Conclusions: This first broad study of gene expressions in blood leukocytes during equine acute LPS-induced systemic
inflammation thoroughly characterized a highly regulated and dynamic innate immune response. These results provide
new insights into the molecular mechanisms of equine systemic inflammation.
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High mortality rates in the equine clinic are related to
the development and progression of severe systemic in-
flammatory conditions like the systemic inflammatory
response syndrome (SIRS) and sepsis. This is seen in dis-
eases as metritis, colitis, small intestinal strangulation,
large intestinal volvulus, pleuropneumonia, and intra-
uterine/neonatal infections [1]. The clinical presentation
in SIRS and sepsis is mainly caused by the immuno-
logical host response [2], which is orchestrated by highly
dynamic and complex interactions of a vast number of
cytokines, hormones, growth factors, and pattern recog-
nition receptors derived from immunologically active
cells, including leukocytes and endothelial cells [2, 3].
The outcome of an individual inflammatory response is
therefore closely related to the specific immunological
capacity of the host [4].
The clinical signs of systemic inflammation are non-
specific [1, 5], and the relation between clinical signs
and the immunological response is not known. Conse-
quently, an exact and timely status of an inflammatory
condition is extremely difficult to obtain on the basis
of clinical parameters, and insights into the early im-
munological disease processes may hold the key for
future diagnostic and therapeutic advances in SIRS
and sepsis.
In human medicine, decades of specific research in
SIRS and sepsis have advanced the understanding of the
underlying cellular processes in human systemic inflam-
mation which, however, does not translate directly into
the equine [6]. In foals, several studies have been con-
ducted comparing innate gene expressions in blood leu-
kocytes in septic patients versus non-septic [7–9] and
healthy foals [10, 11]. In adult horses leukocyte immune
genes have been correlated to type of disease and out-
come in patients with gastrointestinal inflammation and
strangulation [12] while a small number of studies
have had a primary aim of investigating leukocyte
innate immune gene expressions in experimental
lipopolysaccharide- (LPS-) induced systemic inflam-
mation [13–15]. These studies all encourage further
investigations of the diagnostic potential of the immuno-
logical disease processes in equine systemic inflamma-
tion. However, also common for these studies is that a
limited number of genes have been subjected to investi-
gation, and that the highly dynamic nature of the inflam-
matory expression response has been less attended to.
Controlled studies investigating the temporal responses
of more complex gene interactions during equine sys-
temic inflammation are therefore of interest.
The aim of this study was to investigate the expression
of 33 selected blood leukocyte immune genes in an
equine model of LPS-induced acute systemic inflamma-
tion to identify significantly regulated genes and tothoroughly describe the expression dynamics during the
first 24 h of the disease course. The selected genes in-
cluded proteins representing important innate functions
such as amplification of the inflammatory reaction,
pathogen associated molecular pattern recognition, cell
adhesion, apoptosis, signal transduction, and oxidative
burst. The overall aim was to expand our understanding
of the innate immune processes involved in acute sys-
temic inflammation in horses to advance equine clinical
research in systemic inflammatory conditions as SIRS
and sepsis.
Methods
Horses
Six healthy, adult (7.7 ± 5.4 years) Danish Warmblood or
Danish Warmblood cross bred horses (2 geldings, 4
non-pregnant mares) with an initial body weight of
490 ± 39 kg and body condition score [16] of 4.5 ± 0.8
were included in the study. Before the experiment a
complete clinical examination with standard blood
hematological and biochemical analyses was per-
formed. Only horses with unremarkable clinical and
laboratory findings [17] were included in the study.
Horses were housed in individual 3 x 4 m box stalls in
a barn maintained at a temperature of 12 ± 1 °C. They
were fed an equine commercial grain mixture twice
daily and had access to water and hay ad libitum. All
horses were dewormed with ivermectin (Maximec®)
and vaccinated against equine influenza and tetanus
(ProteqFlu-Te®) prior to the study.
Experimental design
The horses were part of a larger randomized experimen-
tal cross over study involving LPS-induced endotoxemia
and synovitis. Horses included in the present study re-
ceived an intravenous injection of 1 μg LPS/kg bwt be-
fore or after an intra-articular administration of 3 μg
LPS. Treatments were given on two separate occasions
with a four week wash out period in between to elimin-
ate possible effects of LPS tolerance. LPS derived from
Escherichia coli strain 055:B5 (#L2880, Sigma-Aldrich
Denmark) was diluted in isotonic saline to a total vol-
ume of 15 ml and administered over one minute
through a jugular vein catheter. Blood samples for
RNA extraction were collected in PAXgene Blood
RNA Tubes (Qiagen/BD Company) before induction
at times −120, −96, −24, and 0 h, and at post-
induction hour (PIH) ½, 1, 1½, 2, 2½, 3, 3½, 4, 5, 6,
8, 10, 12, 16, 20, and 24. All 4 pre-induction samples
were taken in the morning, and the sample at PIH 0
was taken within half an hour before LPS-injection.
The first 5 ml blood were drawn in a separate syringe and
discarded. According to the manufacturer’s instruction
PAXgene blood tubes were gently inverted 8–10 times
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before storage at −80 °C until mRNA extraction. All
experimental procedures were approved by the Danish
Animal Experiments Inspectorate (2011/561 − 1996)
and carried out in agreement with the Danish Animal
Testing Act.
Evaluation of clinical and hematological signs
Examinations comprising general condition, rectal
temperature (RT), heart rate (HR), respiratory rate (RR),
borborygmus score, whole blood white blood cell count
(WBC), and total neutrophil, lymphocyte, and monocyte
counts were performed serially according to Table 1 to
evaluate soundness of horses during the pre-induction
period (PIH −120 to PIH 0) and to monitor post-
induction disease progression and severity. Borborygmus
was assessed on the ventral and dorsal abdomen on both
sides and scored as ileus = 0, significantly decreased = 1,
slightly decreased = 2, normal = 3. Thus, in total borbo-
rygmus score per horse for each time point ranged 0
(complete ileus) to 12 (normal borborygmus). Total
and differential counts of white blood cells were mea-
sured with an automated cell counter (ADVIA 2120
hematology analyser, Siemens Healthcare Diagnostics
Inc., Deerfield, Illinois, USA). At PIH 2, the following
criteria were used to confirm SIRS: the presence of
two or more of the following symptoms; RT < 36.7
or > 38.6 °C, HR > 50 beats/min, RR > 25 breaths/min,
and WBC < 5.000 or > 14.500 cells/mm3 [1].
Target genes
Relative gene expression in blood leukocytes were estab-
lished by quantification of specific mRNA for the follow-
ing genes: IL1B, IL1RN, IL2, IL4, IL6, IL6ST, IL8, IL10,
IL15, IL17, IL18, TNF, TLR4, TLR9, SELL, ITGAM,Table 1 Clinical and hematological evaluations during pre-induction
PIH −120 PIH −96 PIH −24 PIH 0 PIH 1
Rectal temperature (°C) 37.9 ± 0.3 37.5 ± 0.4 37.7 ± 0.2 37.8 ± 0.3 38.1 ± 0.5
Heart rate
(beats per minute)
38 ± 4 35 ± 5 37 ± 5 40 ± 8 52 ± 9
Respiratory rate
(breaths per minute)
18 ± 11 14 ± 2 13 ± 4 16 ± 4 –
Borborygmus scorea 11.3 ± 0.8 11.5 ± 0.8 11.7 ± 0.8 11.7 ± 0.5 3.8 ± 2.9^
WBC (10^9 cells/L) 8.2 ± 1.7 7.1 ± 1.4 8.0 ± 2.0 7.5 ± 1.7 2.0 ± 0.9^
Total neutrophil count
(10^9 cells/L)
4.5 ± 0.7 3.5 ± 0.5 4.0 ± 1.1 4.0 ± 0.9 0.2 ± 0.1^
Total lymphocyte count
(10^9 cells/L)
3.0 ± 1.0 2.9 ± 1.1 3.1 ± 1.1 2.8 ± 1.1 1.7 ± 0.8
Total monocyte count
(10^9 cells/L)
0.4 ± 0.2 0.4 ± 0.1 0.4 ± 0.2 0.4 ± 0.2 0.1 ± 0.03^
Pre-induction period: PIH −120 – PIH 0. Post-induction period: PIH 1 – PIH 24. aBorb
scored as ileus = 0, significantly decreased = 1, slightly decreased = 2, normal = 3. In
ileus) to 12 (normal borborygmus). ^ denotes statistical significant difference (p < 0
values (ref) are according to Aiello [17]ITGAX, TGFB, HMGB1, MIF, CD14, NKAP, MAPK14,
FAS, BID, CASP3, BCL2L1, MPO, MMP8, TIMP1, CCL5,
SOD2, GSF2 (gene names and functional classes are
listed in Additional file 1).
Total RNA extraction and quality analysis
Total cellular RNA was extracted from PAXgene blood
samples using PAXgene Blood miRNA Kits (Qiagen/BD
Company) according to the manufacturer’s instructions.
All RNA samples were treated with RNase-Free DNase
sets (Qiagen/BD Company). Concentration and purity of
total extracted RNA was determined by spectrophoto-
metric analyses (NanoDrop ND-1000 spectrophotom-
eter, Saveen and Werner AB, Limhamn, Sweden). The
concentration was measured at optical density (OD)260,
while assessment of purity was based on OD260/280
and OD260/230 ratios. Samples containing less than
20 ng RNA/μL (9 % of samples) were evaporated
(37 °C) to increase RNA concentrations using a SpeedVac
Concentrator (SPD111V, Thermo Scientific, Slangerup,
Denmark). RNA integrity was estimated via capillary
electrophoresis in an Agilent 2100 Bioanalyzer (Agilent
Technologies, Naerum, Denmark) using RNA 6000 Nano
Kits (Agilent Technologies). Each total RNA sample was
assigned an RNA Integrity Number (RIN) from 1–10, with
10 being non-degraded RNA [18]. Mean RIN value ± SD of
all samples was 8.7 ± 0.9.
cDNA synthesis
Samples containing extracted RNA were DNase treated
to eliminate genomic DNA and converted into first-strand
cDNA by reverse transcription using a Tprofessional
TRIO 3x48 (Fisher Scientific) and QuantiTect Reverse
Transcription Kits (Qiagen/BD Company) according to the
manufacturer’s instructions. In brief, 300 ng of total RNAand post-induction periods (mean ± SD)
PIH 2 PIH 4 PIH 8 PIH 16 PIH 24 Ref
38.9 ± 0.9^ 39.9 ± 0.9^ 38.4 ± 0.3 38.4 ± 0.2 38.1 ± 0.5 37.3 - 38.3
56 ± 8^ 43 ± 8 50 ± 5 54 ± 9^ 53 ± 13^ 28 - 40
18 ± 8 17 ± 5 28 ± 22 12 ± 5 15 ± 8 10 -14
3.8 ± 3.3^ 6.5 ± 2.5^ 9.5 ± 2.9 9.8 ± 3.3 9.8 ± 4.4
1.7 ± 1.0^ 2.7 ± 1.6^ 9.5 ± 3.2 12.9 ± 2.8^ 14.1 ± 2.7^ 6 - 12
0.3 ± 0.3^ 1.6 ± 1.3 8.4 ± 2.9^ 10.9 ± 2.2^ 11.6 ± 2.5^ 3 - 6
1.3 ± 0.7^ 1.0 ± 0.4^ 0.7 ± 0.4^ 1.5 ± 1.0^ 2.1 ± 1.3 1.5 - 5
0.04 ± 0.03^ 0.04 ± 0.03^ 0.1 ± 0.04^ 0.2 ± 0.1^ 0.2 ± 0.1^ 0 - 0.6
orygmus was assessed on the ventral and dorsal abdomen on both sides and
total, borborygmus score per horse for each time point ranged 0 (complete
.0063) of post-injection levels compared with baseline levels at PIH 0. Reference
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transcriptase enzyme and a mix of random primers and
dNTPs (1:4) were added, and samples incubated for
15 min at 42 °C. Finally, enzymes were denatured for
3 min at 95 °C and cDNA cooled down to 4 °C. Two separ-
ate cDNA replicates were performed for each sample and a
non-reverse transcriptase control included. The cDNA
samples were diluted (1:7.7) in low TE-buffer (VWR-Bie &
Berntsen, Herlev, Denmark) and stored at −20 °C until
pre-amplification procedures.
Specific primer design
Gene specific primer pairs were designed using Primer3
(http://frodo.wi.mit.edu/primer3). Nucleic acid sequences
were obtained from a free online genome database (http://
www.ensembl.org/Equus_caballus/Info/Index). BLAST
(http://blast.ncbi.nlm.nih.gov/Blast.cgi) searches were per-
formed to ensure the absence of intraspecies polymor-
phisms at the primer site. When possible, primers were
designed to span an intron to prevent possible amplifica-
tion of contaminating genomic DNA. Primers were synthe-
sized at TAG Copenhagen (Copenhagen, Denmark) or
Sigma-Aldrich (Denmark). Transcript IDs, primer se-
quences, amplicon lengths, reaction efficiencies, and cor-
relation coefficients are shown in Additional file 1. Primer
amplification efficiencies, correlations and dynamic ranges
were acquired from standard curves constructed from
three separate dilution series of pooled pre-amplificated,
exonuclease treated cDNA with the following dilutions:
1:3, 1:9, 1:27, 1:81, 1:243, and 1:729. The pool consisted of
cDNA from every 4th sample representing different sample
times, animals, treatments, and cDNA-replicates. After
completed qPCR many of the samples showed a very low
expression level of IL-2 and IL-6. To cover the dynamic
range of IL-2 and IL-6 an additional standard curve was
made from a dilution series of a pool of cDNA samples
showing high expression levels of IL-2 and IL-6 to calculate
primer amplification efficiencies and correlations for these
specific genes. Efficiencies between 0.91 and 1.12 and cor-
relations above 0.97 were accepted.
Pre-amplification and exonuclease treatment
A 200 nM primer pair mix in low TE-buffer was pre-
pared combining equal amounts of all primers used in
the study (Additional file 1). Five μL of TaqMan PreAmp
Master Mix (Applied Biosystems), 2.5 μL of the primer
pair mix, and 2.5 μL of cDNA were mixed and incubated
at 95 °C for 10 min followed by 16 cycles of 95 °C for
15 s and 60 °C for 4 min. To remove excess nucleotides
pre-amplified cDNA was incubated with 4 μL of 4U/μL
exonuclease for 30 min at 37 °C, followed by 15 min at
80 °C. An aliquot of the cDNA was saved for preparation
of a dilution series, and finally cDNA was diluted 1:7 in
low TE-buffer before quantitative real-time PCR (qPCR).qPCR
Quantitative PCR was performed in a 48.48 Dynamic
Array Integrated Fluidic Circuits (IFC) controller
(Fluidigm, CA, USA), which combines 48 samples with
48 primer sets in 2304 separate, simultaneous reactions
as previously described in Skovgaard et al. [19]. In brief,
for each of the 48 cDNA sample lanes on the Dynamic
Array chip, a ‘sample mix’ consisting of 1.5 μL of
specific pre-amplified exonuclease-treated cDNA,
3 μL of TaqMan Gene Expression Master Mix (Applied
Biosystems), 0.3 μL of 20X DNA Binding Dye Sample
Loading Reagent (Fluidigm), 0.3 μL 20X EvaGreen
(Biotium, VWR-Bie & Berntsen), and 0.9 μL low TE-
buffer was prepared. For each of the 48 primer set
lanes on the chip, a ‘primer mix’ consisting of 2.3 μL of a
specific 20 μM forward/reverse primer (see Additional
file 1), 2.5 μL of 2X Assay Loading Reagent (Fluidigm),
and 0.25 μL low TE-buffer was prepared. After priming
the 48.48 Dynamic Array chip in an IFC controller
(Fluidigm), it was loaded with cDNA sample mixes and
primer mixes and again placed in the IFC controller to
combine each of the 48 samples with each of the 48
primers. The chip was subsequently placed in a BioMark
real-time PCR Reader (Fluidigm), where qPCR was per-
formed under the following conditions: 2 min at 50 °C,
10 min at 95 °C (heat activation) followed by 35 cycles
of 15 s at 95 °C (denaturation) and 1 min at 60 °C
(annealing/elongation). After the last cycle melting
curves were generated by heating from 60 °C to 95 °C
(increasing 1 °C/3 s) to confirm a single PCR product.
Each chip included a non-template control (NTC), a
non-reverse transcription control and three interplate
calibrators. Expression data (Cq values) and melting
curves were acquired using Fluidigm Real-Time PCR
Analysis software 3.0.2 (Fluidigm). NTCs and melting
curves were used to monitor for non-specific amplifica-
tion or sample contaminations. Non-reverse transcriptase
controls were used to assess potential DNA contamin-
ation. For both control samples, a minimum of 5 Cq-
values between potential signals and sample signal were
required and only genes with a single melting peak were
accepted for further data analyses.
Pre-processing of data
Expression data were exported to GenEx5 (MultiD,
Göteborg, Sweden) for data pre-processing. Data was
interplate calibrated and corrected for primer efficiencies
for each primer assay individually. Normalization was
done to the reference genes ACTB, TBP, DIMT1, SDHA,
HPRT1, and B2M. These genes were identified as the
most stably expressed reference genes out of 7 candi-
dates using NormFinder [20] and GeNorm [21]. cDNA
technical replicates were averaged, and for a specific
primer set a maximum of 15 % samples with a ΔCq
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cepted. For a specific sample a maximum of 20 %
primer sets with a ΔCq above ±1.2 was accepted. Finally,
relative expression levels were established. For each gene
the expression level was set to 1 for the sample with the
lowest level of expression. Expression levels for the spe-
cific gene in all other samples, irrespective of horse and
time for sampling, were then calculated relative to this
sample during data transformation from Cq (log2) to rela-
tive quantities (RQ) (relative fold change, linear scale).
Descriptive and statistical analyses
Statistical analyses of post-injection levels of clinical and
hematological parameters compared with baseline
levels at PIH 0 were performed using one-way re-
peated measures ANOVA and Dunnett’s post hoc test
(SigmaPlot v. 12.5.). Distribution of data was evalu-
ated by the Shapiro-Wilk normality test and data was
log2-transformed to improve the model fits. Using the
Bonferroni correction to account for multiple testing, stat-
istical significance was defined as P < 0.0063 (significance
level 0.05/8 parameters) for all analyses.
Relative quantities (raw data) were depicted graphically
using SigmaPlot v. 12.5. Baseline expression levels for
each gene were tested for variability in the 4 pre-
induction samples. Post-induction expression levels for
each gene were compared with baseline levels at PIH 0
and significant regulation defined as statistically signifi-
cant differential expression with a change of at least 2.5
fold. For both baseline samples and post-induction
samples statistical differential expression was deter-
mined using a linear mixed model with “time” as fixed
effect, “horse” as random effect (random intercept),
and Dunnett’s post hoc test (R v. 3.1.1.) on log2-
transformed data. Distribution of data was evaluated
by Shapiro-Wilk normality tests and Q-Q plots of the
residuals and found to be approximately log2-normally
distributed. Using the Bonferroni correction to account
for multiple testing, statistical significance was defined
as P < 0.0016 (significance level 0.05/31 genes) for all
analyses.
Results
Clinical and hematological responses
All horses showed characteristic signs of endotoxemia. A
summary of clinical and hematological recordings and
statistical results are listed in Table 1. During the pre-
induction period all horses were bright, alert, and re-
sponsive, and considered healthy on clinical and
hematological examinations. Within the first hour post-
induction all horses started to express signs of general
discomfort including anorexia and mild to moderate
colic (watching flanks/kicking/lying down/rolling). At
PIH 1 and PIH 2 fever, tachycardia, severely decreasedborborygmus, and profound leukopenia were recorded,
and all horses could be classified as having SIRS. At PIH
4 and afterwards the most prominent alterations in
general demeanor were decreased appetite, depression
(with/without recumbency), and mild colicky behavior.
Fever peaked at PIH 4 and WBC and borborygmus
started to increase. At PIH 24 all horses except one
were bright, alert, and responsive, despite ongoing
leukocytosis and increased HR. All horses recovered
without the need for treatment. As seen in Table 1
changes in post-induction WBC primarily reflected
neutropenia (PIH 1 – PIH 4) followed by neutrophilia
(PIH 8 – PIH 24). Decreased total monocyte and to a lesser
degree lymphocyte counts were also seen during the full
post-induction experimental period including a steep de-
cline in monocyte count at PIH 1.
Gene expressions
In the pre-processing of data, three blood samples
(2.9 %) and 4 single expression measurements for a spe-
cific gene (0.1 %) were excluded due to sampling error
or high ΔCq values between technical replicates. The
genes GSF2 and MPO were not subjected to further
analyses due to high sensitivity to genomic DNA
contamination, indications of splice variants, or low
primer efficiency. Thus, a total of 31 genes were
evaluated for differential expression after induction of
systemic inflammation.
For each of the 31 genes except TIMP1 (p-value
0.0013) mean expression levels in 4 consecutive baseline
samples were statistically equivalent. Post-induction
mean expression levels for each gene are depicted in
relative quantities as a function of time in Additional file
2. Table 2 sums up the overall analyses for each gene of
the post-induction expression levels compared with pre-
induction levels at PIH 0. All genes except IL2 showed a
statistically significant differential expression at mini-
mum one time point after LPS-injection (Table 2A).
Out of these the following 22 genes had expression
levels ≥ 2.5 fold changes compared with baseline
levels: IL1B, IL1RN, IL6, IL6ST, IL8, IL10, IL15, IL17,
IL18, TNF, TLR4, SELL, ITGAM, ITGAX, CD14,
MAPK14, CASP3, BCL2L1, MMP8, TIMP1, CCL5,
and SOD2 (Table 2B). Table 2C, D, and E list up-
regulated and down-regulated genes and genes with
alternated up- and down-regulations, respectively.
Statistically significant differential expressions of at
least 2.5 fold are depicted as a function of time in Fig. 1
to show the expression dynamics during the full 24-h
sampling period. Up-regulations are illustrated in red
colors and down-regulations in blue colors. For each
gene, peak up- and down-regulations in fold change
compared with PIH 0 are stated in white numbers. All
other expression levels are depicted in red and blue
Table 2 Evaluation of the overall post-induction expression levels compared with pre-induction levels at PIH 0
All genes 2A: Genes with statistically
significant differential
expression
2B: Genes with statistically
significant differential
expression≥ 2.5 fold
2C: Genes with statistically
significant up-regulation
≥ 2.5 fold
2D: Genes with statistically
significant down-regulation
≥ 2.5 fold
2E: Genes with statistically
significant mixed up- and
down-regulation≥ 2.5 fold
IL1B IL1B IL1B IL1B
IL1RN IL1RN IL1RN IL1RN
IL2
IL4 IL4
IL6 IL6 IL6 IL6
IL6ST IL6ST IL6ST IL6ST
IL8 IL8 IL8 IL8
IL10 IL10 IL10 IL10
IL15 IL15 IL15 IL15
IL17 IL17 IL17 IL17
IL18 IL18 IL18 IL18
TNF TNF TNF TNF
TLR4 TLR4 TLR4 TLR4
TLR9 TLR9
SELL SELL SELL SELL
ITGAM ITGAM ITGAM ITGAM
ITGAX ITGAX ITGAX ITGAX
TGFB1 TGFB1
HMGB1 HMGB1
MIF MIF
CD14 CD14 CD14 CD14
NKAP NKAP
MAPK14 MAPK14 MAPK14 MAPK14
FAS FAS
BID BID
CASP3 CASP3 CASP3 CASP3
BCL2L1 BCL2L1 BCL2L1 BCL2L1
MMP8 MMP8 MMP8 MMP8
TIMP1 TIMP1 TIMP1 TIMP1
CCL5 CCL5 CCL5 CCL5
SOD2 SOD2 SOD2 SOD2
2A: genes with a statistically significant differential expression at minimum one time point after LPS-induction. 2B: genes with statistically significant differential
expression of at least 2.5 fold. 2C, 2D, and 2E: genes with statistically significant up-regulation, down-regulation, and mixed up- and down-regulation, respectively,
of at least 2.5 fold. All genes listed in 2A – 2E had p-values below 0.0001
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corresponding to percent fold change relative to peak
fold change. Time points without a statistically signifi-
cant differential expressions of at least 2.5 fold compared
with PIH 0 are left white. Significant regulation of
mRNA expression levels were seen in the whole 24 h
sampling period. The first genes to be differentially
expressed were the pro-inflammatory genes IL1B, IL8,
TNF (up-regulated), and CD14 (down-regulated). CCL5
was the most slow-reacting gene with a transcriptiononset at PIH 8. Most up- and down-regulations peaked
within the first 8 h with a high incidence of up-regulated
peaks between PIH 5 and PIH 8. After PIH 8 only
TIMP1 and CCL5 showed its peak expression. Magni-
tudes of mean peak expression varied within 217 fold
up-regulation (MMP8) and 23 fold down-regulation
(CD14). A slight majority of the genes were still differ-
entially expressed at PIH 24 although most of them
were only weakly to moderately expressed at this time
point.
Fig. 1 Expression dynamics during the 24-h experimental period. Statistically significant differential expressions of at least 2.5 fold compared
with baseline levels at PIH 0 are depicted as a function of time (rounded to nearest integer). Up-regulations are illustrated in red shades and
down-regulations in blue shades. For each gene, peak up- and down-regulations in fold change are stated in white letters. All other expression
levels are depicted in red or blue shades, respectively, in percent fold change relative to peak fold change. Time points without a statistically
significant differential expressions of at least 2.5 fold compared with PIH 0 are left white
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Innate leukocyte immune gene expressions have only
been scarcely studied in in vivo equine systemic inflam-
mation. Here, we investigated the expression of 31 se-
lected genes in a serial measurements design to put
special emphasis on the temporal changes of expression
during the disease course of LPS-induced acute systemic
inflammation. Based on number of genes and samples,
the dynamics of equine gene expressions have not been
characterized to this extension before.
Intravenous injection of LPS is a well described model
to induce systemic inflammation in horses and leads to a
consistent response including i.a. fever, tachycardia,
tachypnea, and leukopenia followed by leukocytosis
[22–26]. All horses in this study expressed these
classic signs of LPS-induced systemic inflammation
(Table 1) and could be classified as having SIRS.
They all showed the most severe clinical signs in the
first 2 to 4 h, after which their clinical status grad-
ually improved. The disease was self-limiting with no
need for therapeutic intervention, and at the end of
the 24-h post-induction sampling period all horsesexcept for one showed an unaltered general demeanor. A
similar clinical course for horses subjected to intravenous
LPS was described in Jacobs et al. [26]. The brief clinical
response reflects that LPS was given as a single bolus as
it only exerts its direct effects on the body for a short
period of time due to rapid clearance from circulation
[27]. Horses and humans show comparable responses to
LPS, and a similar course of a well-defined physiological
response of approximately 24 h duration is reported from
healthy humans subjected to LPS-induced systemic in-
flammation [28–30].
All investigated genes except IL2 showed a statistically
significant differential expression compared with pre-
induction levels at PIH 0 at minimum one time point
after LPS-induction. When a criterion of a differential
expression of at least 2.5 fold for assumed biological
relevance was applied, IL4, TLR9, TGFB, HMGB1, MIF,
NKAP, FAS, and BID were filtered out. Thus, the 22
genes listed in Table 2B were found to be significantly
regulated in this case of equine LPS-induced acute sys-
temic inflammation and consequently regarded relevant
for the orchestration of the inflammatory response. A
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cant regulation below 2.5 fold can, however, not be
excluded.
Magnitudes of the observed fold changes differed sub-
stantially between genes with MMP8 showing the great-
est up-regulation with a peak of 217 fold change
compared with baseline levels. This is in line with hu-
man studies of septic shock in children where MMP8
consistently was the highest expressed gene [31]. The
most down-regulated gene, CD14, also showed a prom-
inent regulation with a 23 fold change compared with
pre-induction levels. However, the biological importance
of expression magnitudes in the systemic inflammatory
response is unclear. In general, there is not a strong
correlation between the cellular levels of specific pro-
teins and the abundances of their corresponding mRNA
[32–34], and the biological effects of a highly differen-
tially expressed gene might not be different from a gene
with a lower peak expression value. As an example, IL10
in this study is only moderately differentially expressed
compared with many of the other genes despite that it is
known to be a key moderator of systemic inflammation.
Thus, it might be more explanatory to the orchestration
of systemic inflammation to explore the expression dy-
namics over time, and in the present study numerous re-
peated samplings after a single bolus of LPS enabled the
investigation of the dynamic gene expressions during a
full disease course of acute systemic inflammation from
clinical onset to approximate recovery.
The very diverse and dynamic expression patterns
depicted in Fig. 1 confirm the complexity of the inflam-
matory response. Many of the genes showed alternations
between up- and down-regulations, and while some
remained differentially expressed during the full disease
course, others did not and may thus only add to the in-
flammatory response at certain disease stages. The early
leukocyte response to LPS had a rapid onset as several
of the pro-inflammatory genes showed differential
expression at PIH ½. The response seemed to be very
delicately regulated as the time span between down-
and up-regulations was as short as 2 h (CASP3, PIH
1.5 – 3.5). Just like the clinical response, the gene ex-
pressions reflected the moderate, single-hit challenge. Al-
most all genes showed peak regulation within the first
third (PIH 8) of the full experimental period, and at PIH
24 – where all horses except one showed unaltered gen-
eral demeanors – many of the genes had returned to base-
line levels or to levels of moderate differential expression.
This is in accordance with expression studies of human
LPS-induced systemic inflammation of similar duration
[28, 29, 32]. As an example, Calvano et al. [28] reported in
a microarray study that a number of genes were induced
at PIH 2, that other genes peaked at PIH 4–9, and that
they all had returned to baseline levels by PIH 24.Considering the clinical well-being of the horses at
PIH 24 it was somewhat surprising that many of the
pro-inflammatory genes still showed differential expres-
sion at this time point. However, as the half-life of
mRNA for cytokines and transcriptional activators are
short [35] and as transcription of genes is very rapidly
regulated, the measured expression levels indicate a true
on-going inflammatory reaction. As LPS can only exert
its direct effects on leukocytes during the very short
endotoxemic period preceding clearance [27], it supports
that a pathogen-associated molecular pattern (PAMP)
initiated immune reaction is self-sustained for a period
of time by released cytokines and endogenous danger-
associated molecular patterns (DAMPs). Due to the
termination of the study after 24 h, this study does not
elucidate whether altered expression patterns are present
in horses after resolution of all clinical symptoms. In a
study performed by Fossum et al. [14] leukocyte TLR4
and LY96 (alias MD-2) expression levels were elevated
48 h after the beginning of a 6-h continuous intravenous
LPS-infusion. However, no information on the clinical
status of the horses after 48 h was included.
Generally, genes involved in host responses may be di-
vided into fast reacting genes and genes with a delayed
response as it is done in Calvano et al. [28]. In the
present study, some of the “classic” cytokine genes like
IL1B, IL6, IL8, IL10, and TNF showed a very rapid tran-
scription onset with, except for IL8, a peak up-regulation
coinciding with early clinical symptoms such as tachy-
cardia, severely decreased borborygmus, and profound
leukopenia. The pro-inflammatory genes IL1B, IL6, IL8,
and TNF have shown a similar rapid response to LPS in
other equine LPS-studies [13, 26, 36] as well as in hu-
man studies [32] while IL10 showed a more delayed re-
sponse [32, 36]. Other genes with a rapid transcription
onset (within 3 h) are IL1RN, IL6ST, IL17, BCL2L1,
MMP8, and SOD2.
Anti-inflammatory mediators (IL10 and IL1RN) and
pro-inflammatory mediators (IL1B, IL6, IL8, and TNF)
both showed transcription onsets within the first hour of
LPS-injection indicating that these two counteracting
systems are initiated in temporal proximity. However,
anti-inflammatory genes seemed to have a slightly de-
layed transcription onset and/or peak expression com-
pared with the corresponding pro-inflammatory genes
(IL1B/IL1RN, TNF/IL10). This is biologically plausible as
an initial pro-inflammatory response to PAMPs must be
tightly controlled after onset to avoid excessive amplifi-
cation of these mediators. Damage to host tissues due to
excessive, uncontrolled pro-inflammation is regarded
one of the key factors in the pathogenesis of severe sep-
sis and septic shock [2, 37]. In this regard it is interesting
that MMP8, which is involved in degradation of extra-
cellular matrix, is differentially expressed for 2.5 h before
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TIMP1 [38]. This might, however, suggest the existence
of more specific anti MMP8 genes not tested in this
panel. The anti-inflammatory IL1RN, TIMP1, and SOD2
were all up-regulated in the late part of the experimental
period supporting that a tight orchestration is necessary
for restoration of immunological homeostasis.
Assessed by expression peaks apoptosis is counter-
acted by anti-apoptosis demonstrated by the genes
CASP3 and BCL2L1, respectively. This may reflects a
tight regulation of apoptosis and anti-apoptosis path-
ways, and it is known that members of the TNF super-
family can activate both simultaneously [39]. The other
apoptosis-related genes investigated, FAS and BID, were
not differentially expressed above 2.5 fold in this study.
Whether apoptosis primarily has protective or harmful
consequences during systemic inflammation is still un-
known [3] but CASP3, BCL2L1, FAS, and BID are all re-
ported to be differentially expressed in human patients
suffering from different stages of sepsis [40–42].
Down-regulation of IL15, IL18, SELL, CD14, MAPK14,
CASP3, and SOD2 was measured during the first hours
after LPS-injection. This was somewhat unexpected as
at least some of these mediators are known to be crucial
for initiation of the inflammatory response to bacterial
PAMPs as LPS. As an example, CD14 is part of the pat-
tern recognition complex comprising lipopolysaccharide
binding protein, CD14, TLR-4, and lymphocyte antigen
96 which contributes essentially to the initiation of the
whole downstream inflammatory cascade in the pres-
ence of LPS [2]. However, the early down-regulations
seen in this study do not necessarily reflect intrinsic dif-
ferences in mRNA expression. Instead they may reflect
shifts in the composition of circulating leukocyte sub-
sets. Early leukopenia with relative lymphocytosis
followed by neutrophilic leukocytosis was observed in
the horses as seen in Table 1. Both leukocyte shifts are
well-known phenomena in both LPS-induced and
naturally occurring acute systemic inflammation [1]
and are caused by neutrophil and monocyte margination/
extravasation and release of neutrophil reserves from the
bone marrow, respectively [43, 44]. As seen in Table 1
neutrophils and monocytes were very few in numbers in
blood samples drawn in the first hours after the inflam-
matory onset. This may well explain why CD14, which is
almost exclusively expressed by these two types of white
blood cells, appears as down-regulated in the early in-
flammatory phase. However, the pro-inflammatory cyto-
kines IL1, IL8, and TNF are mainly synthesized by the
exact same cells expressing CD14. The observation of an
early down-regulation of the expression of CD14 but not
of the pro-inflammatory gene expression would therefore
suggest a dramatic increase in pro-inflammatory gene
expression – but not in CD14 expression – more thancompensating for the decrease in circulating numbers of
these cells. TLR4 and the genes encoding adhesion mole-
cules are also known to be involved in the initiation of
the inflammatory response [2, 43], and the decrease in
relative monocyte and neutrophil proportions in circula-
tion blood may likewise explain why no up-regulation of
these particular genes is observed in the early inflamma-
tory response. Shifts in the circulating leukocyte compos-
ition might further account for some of the massive up-
regulations seen across genes at PIH 5 – PIH 8 as espe-
cially neutrophils were getting abundant in circulating
blood. The general abundance in transcribed mRNA at
PIH 5 – PIH 8 can, however, not be entirely attributed to
increases in total neutrophil and monocyte numbers as
these do not peak until PIH 24 (Table 1).
Our results suggest that measurements of whole blood
in vivo leukocyte gene expressions are dependent upon
the composition of the various types of white blood cells
extracted at a given time point during the disease
course. This is supported by both equine [8] and human
[45, 46] studies and is biologically plausible as various
cell types have different capacities for expressing specific
genes. As a result, caution is needed in extrapolating re-
sults from such studies directly to the pathogenesis of
the systemic inflammatory response to endotoxin. In
equine patients with naturally occurring systemic inflam-
mation, leukopenia with profound neutropenia is how-
ever so consistent and well-documented that it is
regarded pathognomonic for the acute stage of disease
[1]. Gene expression analyses on horses with for ex-
ample LPS-induced systemic inflammation may there-
fore very well be relevant for the exploration of
molecular biomarker candidates in patients suffering
from SIRS and sepsis.
Investigation of the immunological processes in sys-
temic inflammation is a major research area in human
medicine as it is believed to hold great promise for fu-
ture diagnostic and therapeutic advancements in SIRS,
sepsis, severe sepsis, and septic shock [47]. Many studies
have identified specific differentially expressed genes in
these disease conditions, either compared with healthy
controls or with patients suffering from a different sub-
group of systemic inflammation [48]. It has, however,
proven extremely difficult to employ individual genes as
biomarkers in clinical practice [48], and recent studies
have turned towards a multi-biomarker approach to bet-
ter encompass the complexity of systemic inflammation
[49–51]. Relatively few leukocyte immune genes have
until now been investigated in the equine, and the re-
sults presented here may contribute to future definition
of a multi-biomarker candidate for early equine systemic
inflammation. However, the present study investigated
the innate immune response to a moderate, single-hit in-
sult by LPS. A more biologically relevant experimental
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Gram-positive PAMPs given repeatedly or as continuous
infusion. Naturally occurring sepsis might be initiated
and maintained by repeated hits of a combination of
PAMPs and endogenous DAMPs, as is thought to be the
case in severely ill horses with ischemic intestinal seg-
ments and transmural migration of gut bacteria to circu-
lating blood. However, the value of LPS studies is
supported by DeClue et al. [52], who only reported of
minor differential effects in the equine leukocyte
cytokine response to combinations of in vitro LPS
and Gram-positive PAMPs (lipoteichoic acid and
peptidoglycan) compared with each of these motifs
alone. In addition, important considerations to take
on from this study to future studies are to relate ex-
pression levels to the concurrent composition of white
blood cells, and to investigate expression dynamics over
time as regulation of gene expressions is orchestrated in
such a highly dynamic manner.
Conclusions
This study investigated the expression of 33 selected
blood leukocyte immune genes in a model of LPS-
induced short-term systemic inflammation in horses. It
was shown that 22 leukocyte genes encoding proteins
involved in i.a. inflammatory reaction amplification,
pathogen associated molecular pattern recognition, cell
adhesion, apoptosis, signal transduction, and oxidative
burst were significantly regulated at at least one time
point during the 24-h experimental period which cov-
ered disease onset to approximate clinical recovery. By
close inspection of the temporal responses, changes in
mRNA abundance revealed a highly regulated and
dynamic nature of this response. This first broad
study of blood leukocyte gene expression in equine
acute LPS-induced systemic inflammation provides
new insights into the molecular mechanisms of nat-
urally occurring equine systemic inflammation and
may contribute to future biomarker development in
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